← All indications
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Subtype terms (2)
More specific conditions that are subtypes of Hematologic Neoplasms in the MeSH hierarchy.
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Bone Marrow Neoplasms
2 drugs experimental
Drugs by status
Approved for this indication (2)
Phase 4 trials (25)
Phase 3 trials (36)
- nitrous oxide
- methylprednisolone
- denosumab
- darbepoetin alfa
- fostemsavir
- iron succinate
- bone marrow derived mesenchymal stem cells
- iron dextran
- pembrolizumab
- olanzapine
- piperacillin
- red blood cells
- allogeneic hematopoietic stem cells
- fedratinib
- cyclophosphamide
- Anti-thymocyte Globulin (Rabbit)
- vancomycin
- nicotinamide
- zoledronic acid
- amphotericin b
- allogeneic cord blood
- allogenic t cell-depleted hematopoietic stem cells
- cd19 car-t cells
- carlecortemcel-l
- gentamicin
- allogeneic blood cells
- tranexamic acid
- oxygen
- multivitamins
- ibandronate
- +6 more
Phase 2 trials (133)
- azacitidine
- vitamin d3
- cmv-specific t-cells
- afuresertib
- allostim
- plerixafor
- anti cd45 monoclonal antibody
- bms-986016
- ridaforolimus
- maraviroc
- urea
- bay1251152
- venetoclax
- benralizumab
- busulfan
- carfilzomib
- cd3,cd19 depleted hematopoietic stem cells
- ceritinib
- clofarabine
- colestipol
- elacytarabine
- ceftolozane
- prednisone
- durvalumab
- duvelisib
- encorafenib
- eravacycline
- fosfomycin
- tacrolimus
- naltrexone
- +103 more
Phase 1 trials (133)
- decitabine
- abt-751
- Vorasidenib
- allogeneic natural killer cells
- activated marrow infiltrating lymphocytes
- atezolizumab
- Eprenetapopt
- belinostat
- blinatumomab
- bpx-501
- c-myb
- cbl0137
- cc-90002
- valproic acid
- selinexor
- eliglustat
- enmd 2076
- entospletinib
- paclitaxel
- ethinyl estradiol
- gilteritinib
- glasdegib
- aldesleukin
- rifampin
- Sovleplenib
- hu5f9-g4
- myeloid progenitor cells
- warfarin
- hydrocortisone
- idarubicin
- +103 more
Organizations
Organization Involved with Phase 4 Indications (12)
- Merck
- Eli Lilly
- Minsk State Clinical Hospital No 9
- Shandong Provincial Hospital
- Shandong University
- Belarusian State Medical University
- Jiao Tong University
- University of Texas at Houston
- University Cancer Foundation
- Duncan Family Institute for Cancer Prevention and Risk Assessment
- Johnson and Johnson
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (15)
- Pfizer
- Sanofi
- Wyeth
- Augusta University
- Monash University
- NHS Blood and Transplant
- University of Georgia
- University of Ottawa
- University of Pavia
- Zhejiang University
- University of Paris
- National Health and Medical Research Council, Australia
- Centre Jean Bernard
- Italian Association for Pediatric Hematology Oncology
- Alberta Cancer Foundation
Organization Involved with Phase 2 Indications (71)
- AbbVie
- Celgene
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- Merck Serono
- Exelixis
- Merck KGaA
- Novartis
- Blueprint Medicines Corporation
- Cellphire, Inc.
- INC Research
- Inovio Pharmaceuticals
- MolMed S.p.A.
- Parexel
- Agios Pharmaceuticals, Inc.
- Ziopharm
- Medical Research Council
- National Cancer Institute (NCI)
- National Cancer Institute, France
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Arizona
- University of London
- Ciusss de L'Est de l'Île de Montréal
- Cornell University
- University of Washington
- Leukemia Research Foundation
- Medical College of Wisconsin
- Melbourne Health
- New York University
- +41 more
Organization Involved with Phase 1 Indications (33)
- Pharmacyclics
- MediGene
- Aprea Therapeutics AB
- Arog Pharmaceuticals, Inc.
- Bayer
- Bellicum Pharmaceuticals
- Celator Pharmaceuticals
- Esanex Inc.
- Forty Seven, Inc.
- Hengrui Therapeutics, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- MacroGenics
- Serenex
- Benovus Bio, Inc.
- Epizyme, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Johns Hopkins University
- Northwell Health
- Ohio State University
- University of Chicago
- Leiden University
- Loxo Oncology
- Karolinska Institute
- University of Oxford
- City of Hope National Medical Center
- North Shore Hospital, New Zealand
- Children's National Medical Center
- Surface Oncology
- The University of Texas, Dallas
- Prelude Therapeutics
- +3 more
Organization Involved with Other Experimental Indications (6)